Rheumatology Academy

Where education meets excellence.
The latest rheumatology CME
& clinical updates you need.

Where education meets excellence.
The latest rheumatology CME & clinical updates you need.

Can We Prevent Psoriatic Arthritis Before Diagnosis?
Can We Prevent Psoriatic Arthritis Before Diagnosis?
Living Rheum
Can We Prevent Psoriatic Arthritis Before Diagnosis?
- Laura Coates, MBChB, MRCP, PhD
Progress and Practical Limits with AI in Psoriatic Arthritis
Progress and Practical Limits with AI in Psoriatic Arthritis
AudioAbstracts
Progress and Practical Limits with AI in Psoriatic Arthritis
- Ryan Quigley
Navigating the Modern PsA Treatment Landscape
Navigating the Modern PsA Treatment Landscape
Living Rheum
Navigating the Modern PsA Treatment Landscape
Rethinking SLE Treatment: Recent Approvals, Novel Targets, and What’s Next
Rethinking SLE Treatment: Recent Approvals, Novel Targets, and What’s Next
Living Rheum
Rethinking SLE Treatment: Recent Approvals, Novel Targets, and What’s Next
- Steve Jackson, PharmD
- Marc Scherlinger, MD, PhD
Exploring Cadherin-6: A Key Driver of Inflammation in Rheumatoid Arthritis
Exploring Cadherin-6: A Key Driver of Inflammation in Rheumatoid Arthritis
Living Rheum
Exploring Cadherin-6: A Key Driver of Inflammation in Rheumatoid Arthritis
- Gary S. Firestein, MD
TYK2 Inhibition with Zasocitinib Delivers Early Benefit Across PsA Domains
TYK2 Inhibition with Zasocitinib Delivers Early Benefit Across PsA Domains
DermConsult
TYK2 Inhibition with Zasocitinib Delivers Early Benefit Across PsA Domains
Adverse Childhood Experiences in cSLE: A Clinically Significant but Underrecognized Burden
Adverse Childhood Experiences in cSLE: A Clinically Significant but Underrecognized Burden
Living Rheum
Adverse Childhood Experiences in cSLE: A Clinically Significant but Underrecognized Burden
- Ryan Quigley
Improving Risk Stratification in Lupus Nephritis: The Role of Urinary Biomarkers
Improving Risk Stratification in Lupus Nephritis: The Role of Urinary Biomarkers
Living Rheum
Improving Risk Stratification in Lupus Nephritis: The Role of Urinary Biomarkers